Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a highly curable lymphoma in which first-line therapy must balance durable disease control with acute and late treatment toxicity. Methods: We retrospectively analyzed 98 patients with newly diagnosed PMBCL who received sintilimab plus R-CHOP (group 1, n = 42) or DA-EPOCH-R (group 2, n = 56).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
